Eli Lilly and Company plans to build a high-tech manufacturing facility in Alzey, Rhineland-Palatinate, Germany.
The facility aims to expand the global manufacturing network for injectable products and devices, meeting the increasing demand for Lilly's medicines, particularly in diabetes and obesity.
With this addition, Lilly will operate six manufacturing sites in Europe, including one in Fegersheim, France, demonstrating a commitment to a strong presence in the region.
Ongoing investments in Europe are expected to create operational synergies, strengthen relationships with universities and governments, and support the early-stage life science ecosystem.
The Alzey facility is projected to employ up to 1,000 skilled workers, including engineers, operators, and scientists, leveraging state-of-the-art technology for manufacturing.
Automation and high-speed manufacturing lines will be utilized in the production process, emphasizing Lilly's commitment to cutting-edge technology.
Scheduled to begin in 2024, the construction of the Alzey site is expected to create around 1,900 jobs, contributing to the local economy.
Germany's highly skilled workforce in the pharmaceutical industry will play a vital role in boosting Lilly's incretin supply when the new site becomes operational in 2027.
Name Eli Lilly
Type New Construction